Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881946 | 0.82 | GBA1 (0.49) | CA2CA12CA1CA9KMT2A | |
| SCHEMBL12605150 | 0.82 | GBA1 (0.49) | CA2CA12CA1CA9KMT2A | |
| SCHEMBL16852254 | 0.80 | BCHE (0.46) | LMNACA2CA12CA1CA9 | |
| SCHEMBL12674211 | 0.80 | MMP2 (0.47) | CA2CA12CA1CA9KMT2A | |
| SCHEMBL13813079 | 0.80 | MMP2 (0.47) | CA2CA12CA1CA9KMT2A | |
| SCHEMBL9072788 | 0.80 | MAPT (0.40) | CA2CA12CA1CA9MAPT | |
| SCHEMBL1899031 | 0.80 | TP53 (0.52) | CA2CA1KMT2AMAPT | |
| SCHEMBL2446838 | 0.79 | PSIP1 (0.52) | CYP1A2MAPTCYP2C9CYP2C19TDP1 | |
| SCHEMBL2646217 | 0.79 | ENPP2 (0.56) | ENPP2LMNAESR1CA2CA12 | |
| SCHEMBL3189814 | 0.76 | TP53 (0.34) | MAPTGAAATMATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222160-B1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8426587-B2 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD. (AU) | 2013-04-23 | — | — | US | disclosed |
| CN-101917845-A | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD | 2010-12-15 | — | — | CN | disclosed |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (AU) | 2010-11-25 | — | — | US | disclosed |
| EP-2222160-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | Pharmaxis Ltd. (AU) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009066152-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (US) | 2009-05-28 | — | — | WO | disclosed |
| US-4119729-A | TREATMENT OF HYPERTENSION | MEAD JOHNSON & COMPANY (US) | 1978-10-10 | — | — | US | disclosed |
| US-4067904-A | ANTIARRHYTHMIA, HYPOTENSIVE | MEAD JOHNSON & COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | VAPA, SLC6A11, VAPB | ENPP2 1553/4885LMNA 954/4885ESR1 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.